
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has enhanced its financial stability through recent equity financings and option exercises, indicating a strengthened position in anticipation of significant revenue growth that is expected to materialize starting in 2026. The company's financing income has notably improved, rising to $284,000 for the quarter and $611,000 year-to-date, reflecting successful financial management and higher earnings from marketable securities. Furthermore, with the establishment of a comprehensive go-to-market infrastructure and positive market feedback on its LIBERTY Endovascular Robotic Surgical System, Microbot is well-prepared for a successful product launch in the U.S. and Europe, fostering a promising outlook for sustained growth in the coming years.
Bears say
Microbot Medical Inc faces several significant risks that contribute to a negative outlook, including potential delays in commercialization and challenges in expanding its product offerings into neurological and cardiovascular segments. The company has yet to achieve profitability and may contend with reimbursement headwinds that could further strain financial performance, coupled with the pressure of device costs eroding hospital margins. Additionally, the lack of robust clinical data from randomized controlled trials poses a substantial risk to the adoption rates of the LIBERTY Endovascular Robotic Surgical System, potentially hindering overall market penetration.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares